Ultralife Corporation, together with its subsidiaries, designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide. The company serves government, defense, and commercial sectors. The company operates in two segments, Battery & Energy Products and Communications Systems. The Battery & Energy Products segment offers lithium 9-volt, cylindrical, thin lithium manganese dioxide, rechargeable, and other non-rechargeable batteries; lithium-ion cells, multi-kilowatt module lithium ion battery systems, and uninterruptable power supplies; and rugged military and commercial battery charging systems and accessories, including smart chargers, multi-bay charging systems, and various cables. The Communications Systems segment provides communications systems and accessories to support military communications systems, such as radio frequency amplifiers, power supplies and cables, connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, and integrated communication systems for fixed or vehicle applications comprising vehicle adapters, vehicle installed power enhanced rifleman appliqué systems, and SATCOM systems. This segment's military communications systems and accessories are designed to enhance and extend the operation of communications equipment, such as vehicle-mounted, manpack, and handheld transceivers. It sells its products under the Ultralife, Lithium Power, McDowell Research, AMTI, ABLE, ACCUTRONICS, ACCUPRO, ENTELLION, SWE Southwest Electronic Energy Group, SWE DRILL-DATA, and SWE SEASAFE brands through original equipment manufacturers, and industrial and defense supply distributors, as well as directly to the United States and international defense departments. In addition, the company sells its 9-volt battery to the broader consumer market through national and regional retail chains and online retailers. The company was founded in 1990 and is headquartered in Newark, New York.
IPO Year: 1992
Exchange: NASDAQ
Website: ultralifecorporation.com
NEWARK, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) today announced the appointment of Jeffrey Luke as Chief Marketing Officer and James Pope as Senior Vice President - Sales & Business Development, Battery & Energy Products, effective January 6, 2025. As Chief Marketing Officer, Jeff will be responsible for reframing our corporate and brand strategies, providing alignment and accountability throughout the global organization. He will collaborate closely with our sales and engineering teams to develop and execute effective go-to-market strategies, ensuring that Ultralife's products and solutions meet the evolving needs of our customers. Jeff brings over two
NEWARK, N.Y., Nov. 22, 2022 (GLOBE NEWSWIRE) -- The Board of Directors of Ultralife Corporation ("Ultralife" or the "Company") (NASDAQ:ULBI) has appointed Michael E. Manna as the Company's President & CEO and as a member of the Board of Directors effective immediately to replace Michael D. Popielec who is leaving the Company. Mr. Popielec will remain with Ultralife as an employee for a sixty-day period ending January 20, 2023 in an advisory role to ensure a smooth leadership transition. In addition to his new role, Mike Manna will retain his leadership position for the Company's Battery & Energy Products segment which he held prior to his appointment as President & CEO. "Over the past twe
NEWARK, N.Y., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the third quarter ended September 30, 2024 as follows: Sales of $35.7 million compared to $39.5 million for the 2023 third quarter, including 1.9% growth in Battery & Energy Products sales and a 58.2% decrease in Communications Systems salesGross profit of $8.7 million, or 24.3% of revenue, compared to $9.8 million, or 24.8% of revenue, for the 2023 third quarterOperating income of $0.5 million, including legal fees and other costs of $0.3 million directly related to the acquisition of Electrochem Solution, Inc., compared to $2.1 for the 2023 third quarterGAAP EPS of $0.02 co
NEWARK, N.Y., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its third quarter results for the period ended September 30, 2024 before the market opens on Friday, November 8, 2024. The Company is reporting third quarter results later than its customary date after its quarter end in order to accommodate the expected closing of its acquisition of Electrochem Solutions, Inc. by the end of October. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on November 8, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable
NEWARK, N.Y., July 25, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the second quarter ended June 30, 2024 with the following highlights: Sales of $43.0 million compared to $42.7 million for the 2023 second quarter, including 8.3% growth in Battery & Energy Products sales to its highest level in the Company's history for this segmentGross profit of $11.6 million, or 26.9% of revenue, compared to $10.6 million, or 24.8% of revenue, for the 2023 second quarterOperating income of $3.9 million, a 6.9% increase over the 2023 second quarterGAAP EPS of $0.18 compared to $0.21 which included recognition of our Employee Retention Credit equivalent to
NEWARK, N.Y., July 11, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its second quarter results for the period ended June 30, 2024 before the market opens on Thursday, July 25, 2024. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on July 25, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register.vevent.com/register/BI3ab77e4ff3d049f3b130d6d227043bba. This will elimin
NEWARK, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the first quarter ended March 31, 2024 with the following highlights: Sales of $41.9 million representing a 31.4% year-over-year increase, including 54.7% growth in medical market salesGross profit of $11.5 million, or 27.4% of revenue, compared to $7.4 million, or 23.3% of revenue for the 2023 first quarterOperating income of $4.1 million versus breakeven for the 2023 first quarterGAAP EPS of $0.18 compared to a loss of $0.02 for the 2023 first quarterAdjusted EBITDA of $5.2 million, a four-fold gain compared to $1.2 million last yearBacklog of $97.4 million exiting the 202
NEWARK, N.Y., April 11, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its first quarter results for the period ended March 31, 2024 before the market opens on Thursday, April 25, 2024. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on April 25, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register.vevent.com/register/BI5d712724df6d4c65bb6496c4ce2d606f. This will elimi
NEWARK, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter Highlights: Sales of $44.5 million representing a 23.4% year-over-year increaseHighest medical sales quarter in Company's historyOperating income of $3.6 million versus $0.2 million for the 2022 fourth quarterAdjusted EPS of $0.18 compared to a loss of $0.03 for the 2022 fourth quarterAdjusted EBITDA of $4.8 million representing a 134.8% year-over-year increaseBacklog of $103.5 million exiting 2023, a 2.4% sequential increase over third quarter Fiscal Year 2023 Highlights: Sales of $158.6 million
NEWARK, N.Y., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its fourth quarter results for the period ended December 31, 2023 before the market opens on Thursday, February 15, 2024. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on February 15, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register.vevent.com/register/BI9f2b6fae66954f53b4517cbe89148738. This
NEWARK, N.Y., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the third quarter ended September 30, 2023 with the following highlights: Sales of $39.5 million representing an 18.8% year-over-year increaseOperating income of $2.1 million versus a loss of $0.6 million for the 2022 third quarterAdjusted EPS of $0.10 compared to a loss of $0.03 for the 2022 third quarterAdjusted EBITDA of $3.5 million representing a 177.3% year-over-year increaseBacklog of $101.1 million exiting the 2023 third quarter "Driven by continuing strong demand from our government/defense and medical customers, sales grew 19% for both the 2023 third quarter and th
NEWARK, N.Y., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its third quarter results for the period ended September 30, 2023 before the market opens on Thursday, October 26, 2023. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on October 26, 2023. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register.vevent.com/register/BI7f14d2264d2242c1adb217d21d75ab21. This wil
NEWARK, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) today announced the appointment of Jeffrey Luke as Chief Marketing Officer and James Pope as Senior Vice President - Sales & Business Development, Battery & Energy Products, effective January 6, 2025. As Chief Marketing Officer, Jeff will be responsible for reframing our corporate and brand strategies, providing alignment and accountability throughout the global organization. He will collaborate closely with our sales and engineering teams to develop and execute effective go-to-market strategies, ensuring that Ultralife's products and solutions meet the evolving needs of our customers. Jeff brings over two
NEWARK, N.Y., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI), today announced it will be presenting at The Benchmark Company's 13th Annual Discovery One-on-One Investor Conference to be held Wednesday, December 11th, 2024 at the New York Athletic Club in New York City. The conference offers emerging growth and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format during which Ultralife will be participating in one-on-one meetings with investors and analysts throughout the day. To schedule a one-on-one meeting with Ultralife, you may submit your request online via the registration link provided. To register
NEWARK, N.Y., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the third quarter ended September 30, 2024 as follows: Sales of $35.7 million compared to $39.5 million for the 2023 third quarter, including 1.9% growth in Battery & Energy Products sales and a 58.2% decrease in Communications Systems salesGross profit of $8.7 million, or 24.3% of revenue, compared to $9.8 million, or 24.8% of revenue, for the 2023 third quarterOperating income of $0.5 million, including legal fees and other costs of $0.3 million directly related to the acquisition of Electrochem Solution, Inc., compared to $2.1 for the 2023 third quarterGAAP EPS of $0.02 co
NEWARK, N.Y., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) completed its acquisition of all outstanding shares of Electrochem Solutions, Inc. ("Electrochem") for $50.0 million in cash from Integer Holdings Corporation (NYSE:ITGR) on October 31, 2024. "I am thrilled to welcome Electrochem to the growing Ultralife Team as another valued member that shares our core values, operating philosophy and strong commitment to both our associates and our long-standing customers. Having achieved our target of closing the acquisition of Electrochem by the end of October, we now look forward to working closely with Khristine Carroll, President – Electrochem, and her experienced
NEWARK, N.Y., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its third quarter results for the period ended September 30, 2024 before the market opens on Friday, November 8, 2024. The Company is reporting third quarter results later than its customary date after its quarter end in order to accommodate the expected closing of its acquisition of Electrochem Solutions, Inc. by the end of October. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on November 8, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable
NEWARK, N.Y., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) has signed a stock purchase agreement to acquire all outstanding shares of Electrochem Solutions, Inc. ("Electrochem") to include its state-of-the-art ISO certified technology and manufacturing facility for $50.0 million in cash from Integer Holdings Corporation (NYSE:ITGR), subject to customary working capital adjustments. The transaction is expected to close by the end of October. Ultralife expects to finance the transaction through its primary lender. Based in Raynham, MA and with over forty years of battery technology experience in critical applications, Electrochem designs and manufactures primary li
PLANO, Texas, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device contract development and manufacturing organization (CDMO), today announced it has entered into an agreement to divest its Electrochem business, which focuses on non-medical applications for the energy, military and environmental sectors, to Ultralife Corporation (NASDAQ:ULBI). Ultralife is acquiring Electrochem for $50 million in cash, subject to customary working capital adjustments, and the transaction is expected to close by the end of October. "The divestiture of our non-medical business is another example of Integer managing our portfolio to accomplish our strategic fi
NEWARK, N.Y., July 25, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the second quarter ended June 30, 2024 with the following highlights: Sales of $43.0 million compared to $42.7 million for the 2023 second quarter, including 8.3% growth in Battery & Energy Products sales to its highest level in the Company's history for this segmentGross profit of $11.6 million, or 26.9% of revenue, compared to $10.6 million, or 24.8% of revenue, for the 2023 second quarterOperating income of $3.9 million, a 6.9% increase over the 2023 second quarterGAAP EPS of $0.18 compared to $0.21 which included recognition of our Employee Retention Credit equivalent to
NEWARK, N.Y., July 11, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its second quarter results for the period ended June 30, 2024 before the market opens on Thursday, July 25, 2024. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on July 25, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register.vevent.com/register/BI3ab77e4ff3d049f3b130d6d227043bba. This will elimin
NEWARK, N.Y., July 01, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) has been added to the Russell 2000® Index and the broad market Russell 3000® Index as part of the 2024 annual reconstitution of the index, effective at the open of the U.S. equity market today, July 1, 2024. "The inclusion of Ultralife in the Russell 2000® Index, one of the most widely used performance benchmarks for small-cap companies, testifies to the substantial improvement in the Company's financial profile and earnings power as we began to realize returns on our customer-driven new product investments and to recapture margins while continuing to advance our transformational projects for our commercia
Benchmark initiated coverage of Ultralife with a rating of Buy and set a new price target of $12.00
The Benchmark Company initiated coverage of Ultralife with a rating of Buy and set a new price target of $12.00
SC 13D/A - ULTRALIFE CORP (0000875657) (Subject)
SC 13G - ULTRALIFE CORP (0000875657) (Subject)
SC 13G/A - ULTRALIFE CORP (0000875657) (Subject)
SC 13G - ULTRALIFE CORP (0000875657) (Subject)
SC 13G/A - ULTRALIFE CORP (0000875657) (Subject)
SC 13G - ULTRALIFE CORP (0000875657) (Subject)
SC 13G/A - ULTRALIFE CORP (0000875657) (Subject)
SC 13G - ULTRALIFE CORP (0000875657) (Subject)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
8-K/A - ULTRALIFE CORP (0000875657) (Filer)
10-Q - ULTRALIFE CORP (0000875657) (Filer)
8-K - ULTRALIFE CORP (0000875657) (Filer)
8-K - ULTRALIFE CORP (0000875657) (Filer)
8-K - ULTRALIFE CORP (0000875657) (Filer)
10-Q - ULTRALIFE CORP (0000875657) (Filer)
8-K - ULTRALIFE CORP (0000875657) (Filer)
8-K - ULTRALIFE CORP (0000875657) (Filer)
SD - ULTRALIFE CORP (0000875657) (Filer)
DEF 14A - ULTRALIFE CORP (0000875657) (Filer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)